Aspirin
Adverse Effect: an increased risk of gastrointestinal ulceration and subtherapeutic aspirin serum concentrations Clinical Management: Monitor patients for excessive gastrointestinal side effects (GI distress, GI bleeding, gastric ulceration) and for decreased effectiveness of aspirin.
Atracurium
Adverse Effect: decreased atracurium effectiveness; prolonged muscle weakness and myopathy Clinical Management: If concurrent therapy is required, monitor the effectiveness of atracurium and adjust the dose as required, especially in patients receiving high-dose Triamcinolone . With prolonged coadministration of these agents, consider allowing the patient to have unparalyzed periods to reduce the total dose of the neuromuscular blocker.
BCG Vaccine
Adverse Effect: an inadequate immunological response to the vaccine Clinical Management: If possible, delay the administration of vaccines, especially live viral or bacterial types, in persons immunosuppressed with large doses of Triamcinolone .
BCG-TB
Adverse Effect: An inadequate immunological response to the vaccine Clinical Management: If possible, delay the administration of vaccines, especially live viral or bacterial types, in persons immunosuppressed with large doses of Triamcinolone . However, the clinical judgment of the responsible physician should prevail.
Pancuronium
Adverse Effect: Decreased pancuronium effectiveness; prolonged muscle weakness and myopathy Clinical Management: If concurrent therapy is required, monitor the effectiveness of pancuronium and adjust the dose as required, especially in patients receiving high-dose Triamcinolone . With prolonged coadministration of these agents, consider allowing the patient to have unparalyzed periods to reduce the total dose of the neuromuscular blocker.
Phenobarbitone
Adverse Effect: Decreased Triamcinolone effectiveness Clinical Management: Monitor for a decreased Triamcinolone therapeutic effect and increase the dose if necessary.
Phenytoin
Adverse Effect: decreased triamcinolone effectiveness Clinical Management: Monitor therapeutic efficacy of the Triamcinolone, a twofold or greater increase in the Triamcinolone
dose may be required with concomitant phenytoin therapy.
Pipecuronium
Adverse Effect: Decreased pipecuronium effectiveness; prolonged muscle weakness and myopathy Clinical Management: If concurrent therapy is required, monitor the effectiveness of pipecuronium and adjust the dose as required, especially in patients receiving high-dose Triamcinolone . With prolonged coadministration of these agents, consider allowing the patient to have unparalyzed periods to reduce the total dose of the neuromuscular blocker.
Primidone
Adverse Effect: Decreased triamcinolone effectiveness Clinical Management: Monitor therapeutic efficacy of the Triamcinolone , especially in individuals who are steroid-dependent such as asthmatics. An increase in the steroid dose may be required with concomitant primidone therapy.
Rifampicin
Adverse Effect: decreased triamcinolone effectiveness Clinical Management: Monitor Triamcinolone effects and increase the dose if necessary; a dose reduction may be necessary if rifampin is discontinued.
Somatropin
Adverse Effect: decreased efficacy of Somatropin Clinical Management: If concurrent use of Triamcinolone and Somatropin cannot be avoided, the dose of the Triamcinolone should be carefully adjusted so as to minimize any growth-inhibiting effects.
Vecuronium
Adverse Effect: Decreased vecuronium effectiveness; prolonged muscle weakness and myopathy Clinical Management: If concurrent therapy is required, monitor the effectiveness of vecuronium and adjust the dose as required, especially in patients receiving high-dose Triamcinolone . With prolonged coadministration of these agents, consider allowing the patient to have unparalyzed periods to reduce the total dose of the neuromuscular blocker. |